Dr. Hussain on the Importance of Next-Generation Sequencing in Prostate Cancer
Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University... Read More
Expert Emphasizes Healthy Lifestyle in Prostate Cancer Care
In an era of multidisciplinary care, it is important to incorporate healthcare experts to help encourage patients with cancer to... Read More
Expert Discusses Optimizing HIFU and Other Strategies in Prostate Cancer
Although High-intensity focused ultrasound (HIFU) is only approved in the United States for prostate tissue ablation, it has demonstrated efficacy... Read More
Considerations for Initiating ADT in Prostate Cancer
Watch the panel.
Apalutamide Added to NCCN Prostate Cancer Guidelines
The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate... Read More
2018 Ushers in New Era of Prostate Cancer Treatment
Upfront taxane-based chemotherapy with docetaxel improved survival in patients with metastatic prostate cancer, according to phase III findings from the... Read More
Surgery, Brachytherapy-based Radiotherapy Induce Similar Survival in Localized Prostate Cancer
Brachytherapy-based radiotherapy and radical prostatectomy produced similar survival results for men with high-risk, localized prostate cancer, according to findings published... Read More
Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer
Preliminary data suggest that patients with cardiovascular disease being treated for metastatic prostate cancer may experience fewer cardiovascular events when... Read More
Dr. Wise on AR-Directed Therapy for Prostate Cancer
David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center,... Read More
Update Sustains OS Benefit of Chemohormonal Therapy in High-Volume Prostate Cancer
Adding docetaxel to androgen-deprivation therapy (ADT) improved overall survival (OS) by nearly 17 months in men with high-volume metastatic hormone-sensitive... Read More